natgillin/translations-raw huggingface dataset:
at least one neutralizing agent in sufficient quantity to position the formulation's pH between 2 and 6, 
- najmanje jedno sredstvo za neutraliziranje, u količini dovoljnoj da pH formulacije bude između 2 i 6,
a PCR fragment with an apparent molecular weight of 96.7 (+/- 1.0) bp resulting from a PCR reaction with the primer pair SEQ ID NO: 1 and 2 
PCR fragment sa očitom molekularnom težinom od 96.7 (+/- 1.0) bp koja proizlazi iz PCR reakcije sa početnicama koje imaju sekvence navedene kao SEQ ID NOs: 1 i 2, i
In an embodiment, the non-fibrous, non-foamed ground glass has been sized with B′) at least one aminoalkyltrialkoxysilane, preferably in amounts of 0.01% by weight to 1.5% by weight, based on the amount of the non-fibrous and non-foamed ground glass. 
Pripravci prema zahtjevu 1 ili 2, naznačen time da je komponenta B) dodatno također sortirana po veličini s B), barem jednim aminoalkiltrialkoksisilanom, poželjno u količinama od 0.01 masenih % do 1.5 masenih %, bazirano na količini bezvlaknastog i nepjenastog smrvljenog stakla.
stem2 [N3-5CN0-2] is reverse complementary or partially reverse complementary with element stem1, and is a consecutive sequence between of 5 to 7 nucleotides; 
peteljka2 [N3-5CN0-2] je reverzno komplementarna ili djelomično reverzno komplementarna sa elementom peteljka1, te je uzastopna sekvenca od između 5 do 7 nukleotida;
1 shows the viable cell density; 
Iprikazuje gustoću vijabilnih stanica;
The composition of any preceding claim, wherein the bacterial strain is of Blautia hydrogenotrophica, Blautia stercoris or Blautia wexlerae. 
Sastav za upotrebu prema bilo kojem prethodnom zahtjevu, pri čemu sastav obuhvaća 10 pojedinačnih sojeva vrste Blautia hydrogenotrophica.
positioning an assembly of a number of fiber mats and possibly filling material on top of the bottom impermeable sheet, 
- < pozicioniranje sklopa broja vlaknastih prostirača i mogućeg punjenja materijala povrh dna nepropusne plohe,
A method as claimed in claim 7 wherein data points in the driver profile are, for at least one profile index, classified against a plurality of possible values for the profile index, and wherein deriving the analysis profile comprises selecting data points corresponding to a subset of possible values of the profile index. 
Postupak prema zahtjevu 8, naznačen time da su podatkovne točke u vozačevom profilu, barem u jednom indeksiranom profilu, određene mnoštvom mogućih vrijednosti indeksiranog profila i pri čemu deriviranje analitičkog profila sadrži odabir podatkovinh točki koje odgovaraju podskupu mogućih vrijednosti indeksiranog profila.
The empty space (34) is of such a construction allowing the liquids to pass through to empty space (7) while prohibiting the bees to exit the hive. 
Prazan prostor (34) ima takvu konstrukciju da omogućuje prolaz kroz prazan prostor (7), dok sprečava izlazak pčela iz košnice.
The core 1 has an inside diameter φi defined by the inner ends of the inward protruding ribs 4 and an outside diameter φe defined by the outer ends of the outward protruding ribs 3. 
Jezgra 1 ima unutarnji promjer O; koji je određen unutarnjim krajevima nabora okrenutih unutra 4, kao i vanjski promjer 1, određen vanjskim krajevima nabora okrenutih vani 3.
Thereby, on the one hand, the process should be kept as simple as possible, and on the other hand, the further processing of the obtained veneer should be facilitated for the user, for example, the manufacturer of furniture. 
Na se taj način, s jedne strane, postupak treba održavati što je moguće jednostavnijim, a s druge strane, daljnja prerada dobivenog furnira trebala bi biti lakša za korisnika, na primjer, za proizvođača namještaja.
an AIDS antiviral agent; 
(a) AIDS antivirusno sredstvo;
The cell media was removed and the cells washed 3 times in 37 °C pre-equilibrated PBS and incubated (on shaker) with 10 µL of a suspension of acceptor beads and 10µL of a solution of test compound or standard compound (0-10 µM) in darkness for 30 min at 25 °C before addition of 30 µl of a suspension of donor beads and further incubation 60-120 min in darkness. 
Stanični medij se ukloni i stanice se isperu 3 puta u na 37 "C s prethodno uravnoteženim PBS i inkubiraju (u šejkeru) sa 10 ui otopinom testnog spoja ili standardnog spoja (0-10 uM) u tami kroz 30 minuta na 25 "C prije dodavanja 30 pl suspenzije donor zrnca i dalje se nastavlja inkubacija 60-120 min u tami.
The composition for the use according to claim 4, wherein said composition comprises 5% to 40%, preferably 10% to 30%, by weight of said ester of alpha-tocopherol on the total weight of the composition. 
Pripravak za uporabu u skladu s patentnim zahtjevom 4, naznačen time što navedeni pripravak sadrži 5% do 40%, poželjno 10% do 30%, po težini navedenog estra alfa-tokoferola u odnosu na ukupnu težinu kompozicije.
The method according to claim 1, wherein the disease or disorder is breast cancer. 
Spoj ili farmaceutski sastav za uporabu prema zahtjevu 3, naznačen time, da bolest ili poremećaj je karcinom Jajnika.
In larger mammals, e.g., humans, an indicated daily dosage is in the range from about 0.5 to about 5,000, preferably from about 1 mg to about 500 mg of a compound of formulae (I) and (Ia), conveniently administered, e.g., in divided doses up to four times a day or in sustained-release form. 
Kod većih sisavaca, npr. kod ljudi, indicirano dnevno doziranje je u rasponu od približno 0,5 do približno 5.000, ponajprije od približno 1 mg do približno 500 mg spojeva formula (I) i (Ia), koji se daju uobičajeno, npr. podijeljeni u doze sve do četiri puta dnevno ili u obliku trajnog oslobađanja.
The control system of claim 1, the at least one memory and the computer program code are configured to, with the at least one processor, cause the control system to generate a control schedule on the basis of the profile information and send the control instructions on the basis of the control schedule, the control schedule specifying one or more times at which to control power flow to or from the first plurality of power units. 
Upravljački sustav (103) sukladno bilo kojem od prethodnih patentnih zahtjeva, pri čemu procesna sredstva (302) su raspoređena na generiraju upravljački raspored na osnovu informacije o profilu i pošalju upravljačke upute na temelju upravljačkog rasporeda, upravljački raspored precizira jedno ili više vremenskih perioda u kojima protječe upravljačko napajanje do i/ili od prvog skupa jedinica (119) napajanja;
is O; and R9 are independently selected from H, alkyl, arylalkyl, cycloalkyl, heterocyclyl, heterocycloalkyl, aryl, heteroaryl and heteroarylalkyl; and R9 can together form a 4, 5,,6, or 7 membered heterocyclyl ring or a 5 or 6 membered heteroaryl ring; 
R*iR? su neovisno izabrani od H, alkil, arilalkil, cikloalkil, heterociklil, heterocikloalkil, aril, heteroaril i heteroarilalkila; RiR? mogu zajedno tvoriti heterociklički prsten od 4, 5, 6 ili 7 članova ili heteroarilni prsten od 5 ili 6 članova; m je dvostruka veza; i n jejednostruka veza.
the shell 14 is fabricated of paperboard, which is selectively coated internally with a thermo-sealable plastic material such as polyethylene, and is formed around a frusto-conical mandrel; 
- < ljuska 14 se proizvede od kartona koji je na odabranim mjestima obložen na unutarnjoj strani s plastičnim materijalom koji se može lijepiti kada je vruć, takvim materijalom kao što je polietilen, pri čemu se oblikovanje ljuske vrši oko jezgre koja ima oblik krnjeg stošca;
total number of reads 
Broj međunarodne objave:
Generally, this coupling reaction is performed out under reductive amination conditions. 
Ovu reakcija kondenzacije općenito se provodi u uvjetima reduktivne aminacije.
Patient packs usually contain one or more blister pack(s). 
(1 koje je laktatna sol, i jedno ili više terapeutskih sredstava.
at least one active agent, to form a composition; shaping the composition to form an extended release matrix formulation; and curing said extended release matrix formulation comprising at least a curing step of subjecting the extended release matrix formulation to a temperature which is at least the softening temperature of said polyethylene oxide for a time period of at least about 1 minute. 
(2) barem jedan aktivni agens, 1 pri čemu je formulacija matrica s produljenim otpuštanjem stvrdnuta pri temperaturi od barem oko 60 *C u vremenskom periodu od oko 1 minute i ima snagu pucanja od barem oko 110 N kada je podvrgnut indentacijskom tostui.
The method of claim 3, further comprising administering a therapeutically effective amount of a pharmaceutical composition comprising a cancer therapeutic agent or a targeted cancer therapeutic agent. The method of claim 3, further comprising administering to the subject a protein-restricted diet. 
Farmaceutski sastav za uporabu iz patentnog zahtjeva 10, pri čemu navedena metoda nadalje obuhvaća davanje terapijskog agensa za rak, ili ciljanog terapijskog agensa za rak, ili dijetu bez proteina.
A pharmaceutical composition produced according to any of the claims 17-21 A composition as defined in any one of claims 1-11, 16 and 22 for use in medicine, such as for treatment of diabetes or obesity, wherein said composition is administered orally. 
Pripravak u skladu s bilo kojim od patentnih zahtjeva 1-21 ili 29-36, naznačen time što je namijenjen upotrebi u medicini, primjerice u liječenju dijabetesa ili pretilosti, gdje se navedeni pripravak primjenjuje oralno.
In these compounds the substituents can be selected in accordance with the following guidance: 
U ovim spojevima supstituenti mogu biti izabrani u skladu sa sljedećom uputom:
The container (22, 122) set forth in claim 7 wherein said spout indicator (149, 249) is circumferential ly aligned with said pour spout (147, 247). 
Spremnik (22, 122) u skladu s patentnim zahtjevom 7, naznačen time što je navedena oznaka kljuna (149, 249) na obodu poravnana s navedenim kljunom za izlijevanje (147, 247).
In preferred embodiments, the weight ratio is greater than 1:1, for example, from about 2 to about 5. 
Polimerni hidrogel u skladu s patentnim zahtjevom 3, naznačen time da je težinski omjer karboksimetilceluloze naspram hidroksietilceluloze u vodenoj otopini veći od 1:1.
A compound according to any one of claims 1 to 20, for use in treating a disorder selected from the group consisting of an immune disorder, inflammatory disorder, cardiovascular disease, myeloma, lymphoma, cancer, and bacterial infection. 
Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 20, naznačen time što je namijenjen upotrebi u liječenju poremećaja koji se bira iz skupine koju čine imunosni poremećaj, upalni poremećaj, kardiovaskularna bolest, mijelom, limfom, rak, te bakterijska infekcija.
A glassy lozenge according to claim 17 wherein at least 75% of component (ii) consists of a non-crystallising form of sorbitol. 
Tableta-pastila prema bilo kojem od prethodnih patentnih zahtjeva, naznačena time što se najmanje 75% komponente (ii) sastoji od ne-kristalizirajućeg oblika sorbitola.
B1, B2 and B3 are independently selected from the group consisting of CR2 and N; W is O or S; 
i R2 su alkalijski metal, pri čemu je alkalijski metal poželjno odabran iz skupine koju čine litij, natrij i kalij,
Z is a polymer of at least 500 Da or a C8-18 alkyl group. 
Z je nosiva skupina, pri čemu je ta nosiva skupina polimer od najmanje 500 Da ili Cg.1g alkil-skupina.
The method of clause 7, wherein the atypical antipsychotic is selected from the group consisting of olanzapine, clozapine, risperidone, quetiapine, aripiprazole, ziprasidone, and pharmaceutically acceptable salts thereof. 
Spoj za uporabu sukladno patentnom zahtjevu 5, naznačeno time, što je netipičan antipsihotik odabran iz skupine sastavljene od olanzapina, klozapina, risperidona, kvetiapina, aripiprazola, ziprasidona i njihovih farmaceutski prihvatljivih soli.
The compound of any one of claims 1-3, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, or the pharmaceutical composition of claim 4, for use in a method of treating, managing or preventing a disease or disorder, wherein the disease or disorder is cancer, a disorder associated with angiogenesis, pain, macular degeneration or a related syndrome, a skin disease, a pulmonary disorder, an asbestos-related disorder, a parasitic disease, an immunodeficiency disorder, a CNS disorder, CNS injury, atherosclerosis or a related disorder, dysfunctional sleep or a related disorder, an infectious disease, hemoglobinopathy or a related disorder, or a TNFa related disorder. 
Spoj prema zahtjevu 5, ili njegova farmaceutski prihvatljiva sol ili stereoizomer, ili farmaceutski pripravak prema zahtjevu 7 za upotrebu u postupku za liječenje, vođenje ili sprječavanje bolesti ili poremećaja, pri čemu bolest ili poremećaj je rak, poremećaj povezan s angiogenezom, bol, makularna degeneracija ili srodni sindrom, kožna bolest, plućni poremećaj, poremećaj povezan s azbestom, parazitska bolest, poremećaj imunodeficijencije, poremećaji SŽS, ozljede SŽS, ateroskleroza ili srodni poremećaj, disfunkcionalni san ili srodni poremećaj, zarazna bolest, hemoglobinopatija ili srodni poremećaj, ili poremećaj povezan s TNFa.
The organic phase was washed with NaHCO3 (sat.), dried over MgSO4, filtered and evaporated. 
Organska faza se ispere s NaHCO; (zas). i osuši preko MgSO,, filtrira i upari.
IL -18BP expressing CHO cells were cultured in suspension in serum-free medium according to the invention with repeated dilutions with fresh medium for 60 days (n=10). 
IL-18BP eksprimirajuće CHO stanice uzgojene su u suspenziji u mediju bez seruma sukladno izumu uz ponavljana razrjeđenja svježim medijem tijekom 60 dana (n=10).
The deuterated benzopyran compound or pharmaceutically acceptable salt according to claim 2, characterized in that the compound is 6-chloro-8-(methyl-D3)-2-(trifluoromethyl)-2H-chromene-3-carboxylic acid or a salt thereof. 
Deuterirani benzopiranski spoj ili farmaceutski prihvatljiva sol prema patentnom zahtjevu 2, naznačeno time što je spoj 6-kloro-8-(metil-D3)-2-(trifluorometil)-2H-kromen-3-karboksilna kiselina ili njegova sol.
precipitating IgG from the suspension formed in step (c), in a third precipitation step, with between about 22% and about 28% alcohol at a pH of between about 6.7 and about 7.3 to form a third precipitate; 
obrada suspenzije stvorene u koraku (c) s deterdžentom, taloženje IgG iz suspenzije s oko 20% do oko 30% alkohola i na pH-vrijednosti od oko 6,7 do oko 7,3, za tvorbu drugog taloga,
The compound of claim 1, where X is H and has formula f: 
Spoj u skladu s patentnim zahtjevom 1, naznačen time, da je X H i ima formulu f:
A composition according to claim 7, characterized in that said C1-C4-alkyl group is methyl and/or ethyl and said C1-C4-carboxy group is carboxy methyl. 
Pripravak u skladu s patentnim zahtjevom 7, naznačen time što je navedena C1-C4-alkilna skupina metil i/ili etil, a navedena C1-C4-karboksi skupina je karboksimetil.
The method of any of paragraphs 1-9, wherein the formulation further comprises one or more pharmaceutically acceptable excipients, wherein the one or more excipients are selected from the group consisting of water, surfactants, vitamins, natural extracts, preservatives, chelating agents, perfumes, preservatives, antioxidants, chelating agents, hair coloring agents, proteins, amino acids, humectants, fragrances, emollients, penetrants, thickeners, viscosity modifiers, hair fixatives, film formers, emulsifiers, opacifying agents, propellants, liquid vehicles, carriers, salts, pH adjusting agents, neutralizing agents, buffers, hair conditioning agents, anti-static agents, anti-frizz agents, anti-dandruff agents, and combinations thereof. 
Postupak prema bilo kojem od zahtjeva 1-8, naznačen time da formulacija dalje sadrži jedno ili više kozmetički prihvatljivih pomoćnih sredstava, pri čemu je jedno ili više pomoćnih sredstava odabrano iz skupine koju čine voda, površinski aktivna sredstva, vitamini, prirodni ekstrakti, konzervansi, sredstva za kelatiranje, parfemi, sredstva za održavanje, antioksidanti, sredstva za kelatiranje, sredstvo za bojenje kose, proteini, aminokiseline, sredstva za vlaženje, mirisi, emolijenti, sredstva za prodiranje, sredstva za zgušnjavanje, modifikatori viskoziteta, učvršćivači za kosu, sredstva koja tvore film, emulgatori, sredstva za zamućivanje, propelanti, tekuća sredstva, nosači, soli, sredstva za podešavanje pH, sredstva za neutralizaciju, puferi, sredstva za regeneraciju kose, antistatička sredstva, sredstva protiv kovrčanja, sredstva protiv prhuti i njihove kombinacije.
The use of claim 1, wherein the neuroprotective drugs are drugs used for treatment of neuron damage caused by hypoxia. 
5o-androstan-3B,5,6f-triol za uporabu u skladu s patentnim zahtjevom 1, pri čemu je oštećenje neurona uzrokovano hipoksijom.
not allowing the sliding of the centring protrusion (9') along the longitudinal development of the portions (4, 5) of the structure (2). 
ne dopušta klizanje centrirajućeg izbočenja (9’) po uzdužnom pružanju dijelova (4, 5) strukture (2).
The compound according to claim 1 having Formula IV: wherein R2 is halo or H; R3 is H; R4 is optionally substituted pyrazole, optionally substituted pyridyl, an optionally substituted pyridinone or a pyridine-N-oxide; and A is: 
Spoj prema zahtjevu 1, naznačen time što ima Formulu IV: [image] gdje je R2 halo ili H; R3 je H; R4 je po izboru supstituirani pirazol, po izboru supstituirani piridil, po izboru supstituirani piridinon ili piridin-N-oksid; i A je:
setting the casted composition and, after complete curing, 
- postavljanje miješanog sastava 1, nakon potpunog stvrdnjavanja,
In another embodiment, the (±)-A9-THC obtained in the Crystallizing Step comprises at least 98% by weight of trans-(-)-A9-THC and trans-(+)-A9-THC based on the total amount of cannabinoids. 
Postupak prema zahtjevu 1, naznačen time da sastav trans-(-)-A*-tetrahidrokanabinola sadrži najmanje oko 98% težinski trans-(-)-A"-tetrahidrokanabinola bazirano na ukupnoj količini od trans-(-)-A-tetrahidrokanabinola i trans-
or a pharmaceutically acceptable salt, hydrate or rotomer thereof. 
[image] [image] ili njegova farmaceutski prihvatljiva sol, hidrat ili rotomer.
The compound according to claim 19, wherein the therapeutically acceptable salt is hydrochloride. 
Spoj u skladu s patentnim zahtjevom 19, naznačen time, da je terapijski prihvatljiva sol hidroklorid.
at least 30 °C for a period of at least two months. 
(c) najmanje 30 *C kroz razdoblje od najmanje dva mjeseca.
Demographics of cases and controls. 
(21) Broj predmeta:
Solid aerosol forming components may be admixed with the substrate and distributed evenly throughout prior to formation. 
Krute tvari za formiranje aerosola mogu se mješati sa supstratom i rasporediti podjednako kroz supstrat prije formiranja.
A pharmaceutical composition according to claim 10, wherein said composition is suitable for administration to a patient by infusion. 
Farmaceutski sastav prema bilo kojem zahtjevu od 11 do 26, naznačen time, da je spomenuti sastav pogodan za primjenu na pacijentu pomoću infuzije.
iii) a third region which comprises a conjugate moiety, a targeting moiety, a reactive group, or a blocking moiety, wherein the third region is covalent linked to the second region. 
treću regiju koja obuhvaća skupinu tvari konjugata ili ciljnu skupinu tvari, dok je treća regija kovalentno povezana na drugu regiju.
if the single rearranged human immunoglobulin light chain variable region is derived from a rearranged Vk1-39 gene sequence, the Vk1-39 gene sequence comprises a replacement of at least one non-histidine codon with a histidine codon designed to express a histidine 
(1) jedna preuređena genska sekvenca varijabilne regije humanog imunoglobulinskog lakog lanca sadrži Vx139/JK gensku sekvencu koja se sastoji od zamjene najmanje jednog nehistidinskog kodona histidinskim kodonom dizajniranim da izražava histidin
a control winding; and 
regulirajućeg namota (20); i
Further preferred compounds of formula (I) as defined in embodiment 1) are selected from the group consisting of: 
Spoj formule (I) prema zahtjevu 1, naznačen time, da je odabran iz skupine koju čine:
The dark solution was allowed to cool to room temperature, dichloromethane (12.5 ml) was added and the solution was washed with H2O (12.5 ml). 
Tamnu otopinu ostavi se da se ohladi do sobne temperature, doda se diklormetan (12,5 ml), a otopinu ispere s H2O (12,5 ml).
is hydrogen, halogen, OH, or C1-C6 alkyl wherein said C1-C6 alkyl is substituted with 0-6 halogen and wherein up to two non-adjacent CH2 units of said C1-C6 alkyl may be replaced with -O-; is hydrogen, halogen, or C1-C6 alkyl wherein said C1-C6 alkyl is substituted with 0-6 halogen and wherein up to two non-adjacent CH2 units of said C1-C6 alkyl may be replaced with -O-; and 
R? je vodik, halogen, OH ili skupina C,-Ce alkil, pri čemu je navedena skupina C,-Cg alkil supstituirana s 0-6 halogena 1 pri čemu do dvije CH? jedinice navedene skupine Ci-C4 alkil koje nisu susjedne, mogu biti zamijenjene s -O-; R' je vodik, halogen ili skupina C;-Cx alkil, pri čemu je navedena skupina C,-C4 alkil supstituirana s 0-6 halogena 1 pri čemu do dvije CH? jedinice navedene skupine Ci-C4 alkil koje nisu susjedne, mogu biti zamijenjene s -O-; i
X may be any suitable leaving group, in particular a halide. 
X može biti bilo koja prikladna izlazeća skupina, posebno halogenid.
According to one embodiment of the invention, the stoichiometric ratio of solid mineral alkaline in powder form to concentrated mineral acid used for the grasping layer is equal to or more than 5:1, preferably more than 10:1, more preferably more than 15:1. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time, da je stehiometrijski omjer krute mineralne lužine u praškastom obliku i koncentrirane mineralne kiseline veći od 10: 1, poželjno više od 15:1, poželjnije više od 20:1.
The “molecular weight” of branched polyalkyleneimines prior to modification in the meaning of the present invention is the weight average molecular weight as measured by light scattering (LS) techniques. If said salt of a C5-C28 fatty acid is a monoalcohol primary alkanolamine salt, said monoalcohol primary alkanolamine is preferably selected from the group comprising ethanolamine, propanolamines, butanolamines, pentano famines and mixtures thereof. 
Postupak prema bilo kojem zahtjevu od 1 do 12, naznačen time, da ako je navedena sol Cs - C2g masne kiseline sol primarnog mono-alkohol alkanolamina, navedeni primarni monoalkohol alkanolamin je odabran iz skupine koja sadrži etanolamin, propanolamine, butanolamine, pentanolamine i njihove smjese, te je poželjno sol 1-amino-2- propanol Cs5 - Cxg masne kiseline.
Acamprosate, or a salt thereof, or a sustained-release formulation thereof, for use in combination with baclofen or a salt thereof, or a sustained-release formulation thereof, and riluzole, or a salt thereof, or a sustained-release formulation thereof, in a method of treatment of ALS or a related disorder selected from Primary Lateral Sclerosis (PLS), Progressive Muscular Atrophy (PMA), Pseudobulbar Palsy and Progressive Bulbar Palsy (PBP) and Fronto Temporal Dementia (FTD). 
Akamprosat, ili njegova sol, ili njegova formulacija s produženim otpuštanjem, za uporabu u kombinaciji s baklofenom, ili njegovom soli, ili njegovom formulacijom s produženim otpuštanjem, te riluzolom, ili njegovom soli, ili njegovom formulacijom s produženim otpuštanjem, u postupku za liječenje ALS ili srodnog poremećaja koji se bira od primarne lateralne skleroze (PLS), progresivne mišićne atrofije (PMA), pseudobulbarne paralize 1 progresivne bulbarne paralize (PBP) i frontalno-temporalne demencije (FID).
The method as claimed in claim 9, wherein the bacterial and viral disorders of the upper respiratory tract are caused by influenza viruses. 
Pripravci prema patentnom zahtjevu 9, naznačeni time da bakterijski i virusni poremećaji gornjeg respiratornog trakta potječu od stanja uzrokovanih virusima influence.